Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Study of MEDI4736 and tremelimumab in metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma
jRCT2080223020Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of durvalumab and tremelimumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by AstraZeneca. Started Nov 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223020.